Analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to report $64.82 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Sarepta Therapeutics’ earnings, with the lowest sales estimate coming in at $60.00 million and the highest estimate coming in at $69.34 million. Sarepta Therapeutics reported sales of $16.34 million during the same quarter last year, which indicates a positive year over year growth rate of 296.7%. The firm is scheduled to announce its next earnings report on Thursday, April 26th.
According to Zacks, analysts expect that Sarepta Therapeutics will report full-year sales of $302.31 million for the current fiscal year, with estimates ranging from $295.67 million to $312.50 million. For the next financial year, analysts anticipate that the firm will report sales of $486.32 million per share, with estimates ranging from $431.97 million to $530.80 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). The company had revenue of $57.30 million for the quarter, compared to analyst estimates of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The firm’s quarterly revenue was up 961.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.71) EPS.
Several brokerages have recently issued reports on SRPT. BidaskClub raised shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 13th. JPMorgan Chase lifted their price objective on shares of Sarepta Therapeutics from $75.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 14th. Leerink Swann reaffirmed a “positive” rating and issued a $92.00 price objective (up previously from $79.00) on shares of Sarepta Therapeutics in a research note on Tuesday, March 13th. Piper Jaffray reaffirmed an “overweight” rating on shares of Sarepta Therapeutics in a research note on Friday, March 2nd. Finally, HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 2nd. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $78.87.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Sarepta Therapeutics by 39.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 977 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its stake in Sarepta Therapeutics by 140.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 2,493 shares during the last quarter. Prentiss Smith & Co. Inc. acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at approximately $199,000. Arrowstreet Capital Limited Partnership acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at approximately $217,000. Finally, Aperio Group LLC acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at approximately $219,000. Hedge funds and other institutional investors own 84.98% of the company’s stock.
Sarepta Therapeutics stock traded up $1.44 during trading hours on Friday, hitting $79.99. 1,175,330 shares of the company traded hands, compared to its average volume of 1,515,681. The stock has a market cap of $5,260.65, a price-to-earnings ratio of -48.77 and a beta of 1.29. The company has a current ratio of 13.91, a quick ratio of 12.96 and a debt-to-equity ratio of 0.54. Sarepta Therapeutics has a 1-year low of $28.82 and a 1-year high of $84.37.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Sarepta Therapeutics Inc (SRPT) Will Post Quarterly Sales of $64.82 Million” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/20/zacks-analysts-anticipate-sarepta-therapeutics-inc-srpt-will-post-quarterly-sales-of-64-82-million.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.